Skip to main content
OpenTrials
Completed

NCT Number: NCT00862355

Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer

Bioequivalence study of SPARC147609

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects meeting all of the following criteria will be considered for enrollment in the study:
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements.
  • Patients with documented diagnosis of Ovarian Cancer and eligible for receiving a dose 50mg/m2 of Doxorubicin liposome(preferably on no other concomitant medication, however, if considered necessary, to be documented and given).
  • Patients at least 18-years of age or older. iv. Subjects who have no evidence of underlying disease (except ovarian cancer) during screening medical history and whose physical examination is performed within 21 days prior to commencement of the study.
  • Patients with Performance ≤ 2 on the ECOG performance scale. vi. Subjects whose screening laboratory values are within normal limits or considered by the clinical Investigator/Co-Investigator to be of no clinical significance.
  • Informed consent form given in written form.

Exclusion criteria

  • History or presence of significant:
  • Allergy or Significant history of hypersensitivity or idiosyncratic reactions to Doxorubicin Hydrochloride and/or any related compounds etc.
  • Cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
  • Alcohol dependence, alcohol abuse or drug abuse or addiction with any recreational drug within past one year.
  • Clinically significant illness (except ovarian cancer)within 4 weeks before the start of the study v. Positive result to HIV, HCV, RPR and HBsAg.
  • Use of enzyme-modifying drugs (like Phenytoin, Carbamazepine, Barbiturates, Gresiofulvine etc.) in the previous 30 days before day 1 of this study and during the study.
  • Donation of 350 mL or more of blood in the previous 90 days before day 1 of this study.
  • Participation in another clinical trial within the preceding 90 days of study start
  • Subjects who have:
  • Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg
  • Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg
  • Pulse rate below 60/min. or above 100/min

Treatment and study plan

SPARC147609

Drug

IV infusion

Reference147609

Drug

IV infusion

Primary outcomes

  1. 90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference product

    Time frame: 2 cycles

Secondary outcomes

  1. Treatment emergent adverse events

    Time frame: 2 cycles

Sponsors and collaborators

Lead sponsor

Sun Pharma Advanced Research Company Limited

Industry

Registry information

Important dates

Study start
2010
Primary completion
2010
Study completion
2011
First posted
Mar 16, 2009
Registry last updated
May 3, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.